Ectosan® Vet - Variation to Marketing Authorisation enabling a second use of treatment water

Ectosan® Vet 
Variation to Marketing Authorisation enabling a second use of treatment water
An important milestone towards optimal efficiency of Benchmark's
transformational sea lice solution

Benchmark (LSE: BMK), the aquaculture biotechnology company, is pleased to
announce that it has been granted a variation to its Marketing Authorisation
("MA") for Ectosan® Vet  from the Norwegian Medicines Agency ("NoMA").

This variation to the MA enables the re-use of the treatment water for a second
batch of fish, subject to water quality being maintained to the satisfaction of
the prescribing veterinarian, therefore increasing the efficiency of treatments.
This means a producer will be able to treat a salmon farm more efficiently with
a solution that delivers more than 99% efficacy, promotes animal welfare,
reduces mortality and protects the environment - driving sustainability in the
industry. 

This MA variation represents a further important step towards our goal of
optimising the efficiency of our sea lice solution, and further trials are
ongoing to support multiple re-use of treatment water.  

 Trond Williksen, CEO, commented:
 
"We are very pleased to have been granted a variation to the Marketing
Authorisation from the Norwegian Medicines Agency. This represents an important
milestone for the Company and for the industry. Ectosan® Vet and CleanTreat® is
a much needed solution for the industry which continues to show excellent
results with efficacy above 99% as well as good operational efficiency. It is
the first medicinal solution brought to the Norwegian market in over ten years
which addresses one of the biggest challenges in salmon production, while
improving animal welfare, reducing mortality and protecting the environment."

Enquiries:
 
Benchmark Holdings plc	Tel: [phone]
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations 	 
 	 
Numis (Broker and NOMAD)	Tel: [phone]
James Black / Freddie Barnfield / Duncan Monteith	 
 	 
MHP	 
Katie Hunt/Fergal Bettridge-Boyd     	Tel: [phone]                        
  
[e-mail]

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange